# Complex Venous Thromboembolism in a Young Woman With Multisystem Manifestations: A Case Report

**Authors:** Mahmoud A Alswij, Sliman Marina, Mais Musleh, Dani Alokla, Adnan Alhaj Hasan

PMC · DOI: 10.7759/cureus.92328 · 2025-09-14

## TL;DR

A young woman with rare blood clotting issues and genetic factors faced complex health challenges requiring careful treatment.

## Contribution

Highlights the combined effect of mild thrombophilic factors and sickle cell trait in causing severe VTE.

## Key findings

- Patient had multiple genetic mutations and sickle cell trait contributing to thrombosis.
- Mesenteric venous thrombosis was managed with apixaban and clopidogrel due to bleeding risks.
- Case emphasizes the need for comprehensive evaluation in young VTE patients.

## Abstract

Venous thromboembolism (VTE) in adolescents is rare and often necessitates a comprehensive evaluation for both inherited and acquired prothrombotic conditions. We report the case of an 18-year-old female who initially presented with cerebral venous sinus thrombosis (CVST). Anticoagulation with warfarin was complicated by massive gastrointestinal bleeding, followed by deep vein thrombosis (DVT) and recurrent thrombotic events, including superior mesenteric venous thrombosis with bowel infarction. Laboratory investigations revealed sickle cell trait (HbS 38.3%), heterozygous mutations in lymphotoxin alpha (LTA C804A), Factor V R2 (H1299R), and methylenetetrahydrofolate reductase (MTHFR C677T), with normal homocysteine levels. The autoimmune panel was negative apart from borderline high cardiolipin immunoglobulin G (IgG). Owing to recurrent bleeding, anticoagulation proved challenging, and she was ultimately managed with apixaban and clopidogrel. This case illustrates the synergistic impact of multiple mild thrombophilic factors and sickle cell trait, underscores the need to consider mesenteric venous thrombosis in abdominal emergencies, and highlights the clinical challenge of balancing thrombosis prevention with bleeding risk.

## Linked entities

- **Genes:** LTA (lymphotoxin alpha) [NCBI Gene 4049], MTHFR (methylenetetrahydrofolate reductase) [NCBI Gene 4524]
- **Diseases:** venous thromboembolism (MONDO:0005399)

## Full-text entities

- **Genes:** MTHFR (methylenetetrahydrofolate reductase) [NCBI Gene 4524], LTA (lymphotoxin alpha) [NCBI Gene 4049] {aka LT, TNFB, TNFSF1, TNLG1E}
- **Diseases:** sickle cell trait (MESH:D012805), thrombosis (MESH:D013927), bleeding (MESH:D006470), bowel infarction (MESH:D007238), VTE (MESH:D054556), DVT (MESH:D020246), CVST (MESH:D012851), thrombophilic (MESH:D019851), HbS (MESH:D000755), mesenteric (MESH:D008639), gastrointestinal bleeding (MESH:D006471)
- **Chemicals:** warfarin (MESH:D014859), apixaban (MESH:C522181), homocysteine (MESH:D006710), clopidogrel (MESH:D000077144)
- **Mutations:** H1299R, C804A, C677T

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12521816/full.md

---
Source: https://tomesphere.com/paper/PMC12521816